Abbott Laboratories stock (US0028241000): Q1 earnings beat estimates with $11.16B revenue

Abbott Laboratories reported Q1 revenue of $11.16 billion and EPS of $1.15, surpassing analyst expectations. Shares closed at $84.24 on May 8, 2026, down 3.19% that day amid a year-to-date decline of 32.8%.

Abbott Laboratories released its first-quarter results, posting revenue of $11.16 billion and earnings per share of $1.15, beating consensus estimates of $1.14 EPS according to MarketBeat as of 05/08/2026. The healthcare giant's stock fell 3.19% to $84.24 on May 8, 2026, on the NYSE, reflecting broader pressures despite the earnings beat.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Abbott Laboratories
• Sector/industry: Healthcare / Medical Devices & Diagnostics
• Headquarters/country: Chicago, USA
• Core markets: US, Europe, Asia
• Key revenue drivers: Diagnostics, Nutritional Products, Medical Devices
• Home exchange/listing venue: NYSE (ABT)
• Trading currency: USD

Abbott Laboratories: core business model

Abbott Laboratories develops and sells health care products worldwide, spanning diagnostics, nutritional products, branded generic medicines, and medical devices. The company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. This diversified model supports stable revenue streams, with diagnostics gaining prominence post-COVID through tests like BinaxNOW.

Headquartered in Chicago, Abbott focuses on innovation in areas like continuous glucose monitoring via its Freestyle Libre system, which has become a key growth driver in diabetes care. The business emphasizes direct-to-consumer and B2B sales, serving hospitals, clinics, and retail channels globally.

Main revenue and product drivers for Abbott Laboratories

In Q1 2026, revenue reached $11.16 billion, driven by strong diagnostics and medical devices performance according to MarketBeat as of 05/08/2026. EPS of $1.15 topped expectations, highlighting operational efficiency with trailing twelve months EPS at $3.57. Nutritional products like Ensure and Pedialyte remain staples, while established pharmaceuticals contribute in emerging markets.

The stock has faced headwinds, declining 32.8% year-to-date to $84.24 as of May 8, 2026, from $125.30 at year-start per MarketBeat data. Analysts maintain a Moderate Buy consensus with a $119.43 price target, suggesting 41.8% upside potential.

Industry trends and competitive position

Abbott holds a strong position in the $500+ billion global medtech market, competing with Medtronic, Boston Scientific, and Roche in diagnostics. Trends like personalized medicine and remote monitoring favor Abbott's Libre portfolio, which leads in CGM adoption. US investors benefit from Abbott's heavy exposure to the domestic health care sector, where Medicare reimbursement dynamics directly impact revenues.

Why Abbott Laboratories matters for US investors

Listed on the NYSE, Abbott Laboratories offers US investors access to a blue-chip healthcare name with significant domestic revenue—over 40% from the US. Its role in diagnostics and diabetes management aligns with aging population trends and rising chronic disease prevalence in America.

Conclusion

Abbott Laboratories delivered a Q1 earnings beat with robust revenue growth, yet shares remain under pressure amid market challenges. The company's diversified portfolio and innovation pipeline position it well in healthcare trends. Investors track upcoming catalysts like further earnings and product launches for direction.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.